Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca

Roche, Regeneron, Cell Therapeutics, and AstraZeneca could all make health-care headlines this morning. Here's why.

Mar 3, 2014 at 9:27AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Let's take a look at four stocks -- Roche (NASDAQOTH:RHHBY), Regeneron (NASDAQ:REGN), Cell Therapeutics (NASDAQ:CTIC), and AstraZeneca (NYSE:AZN) -- which could all loom large in health-care headlines this morning.

Roche's MetMab fails to help lung cancer patients
First and foremost, Swiss pharmaceutical giant Roche (NASDAQOTH:RHHBY) announced that it had halted a study of its experimental lung cancer drug, MetMab. The recommendation to halt the study was made by an independent data monitoring committee on grounds that MetMab wasn't shown to work in treating non-small cell lung cancer (NSCLC) when taken with Roche's (NASDAQOTH:RHHBY) Tarceva.

Although MetMab had been considered a potential blockbuster drug by several analysts, the drug's failure shouldn't have any long-term effect on Roche's (NASDAQOTH:RHHBY) stock, according to analysts at J. Safra Sarasin, since it isn't considered a major catalyst for the company in 2014. However, this is the second recent setback for Roche (NASDAQOTH:RHHBY), following the late-stage failure of its schizophrenia drug bitopertin in January.

Regeneron and Bayer's Eylea inches closer to a market approval for DME
Regeneron (NASDAQ:REGN) and Bayer (NASDAQOTH:BAYRY) just announced that Bayer's (NASDAQOTH:BAYRY) Japanese subsidiary Bayer Yakuhin has submitted an application for the marketing authorization of its eye drug Eylea as a treatment for diabetic macular edema (DME) to the Japanese government.

Eylea is currently approved in the U.S. for the treatment of wet age-related macular degeneration (AMD) and macular edema following central retinal vein occlusion (CRVO). The drug is approved in the EU and other countries for the same two indications.

Eylea's primary competitor, Novartis' Lucentis, is approved for the same indications along with three others (the first two indications in the U.S. and Europe, and the third in Europe) -- macular edema following branch retinal vein occlusion (BRVO), DME, and chronic neovascularization (CNV) secondary to pathologic myopia.

Regeneron (NASDAQ:REGN) and Bayer (NASDAQOTH:BAYRY) are eager to match Lucentis' indications, and have already made regulatory submissions in the U.S. and Europe for Eylea as a DME treatment, and a submission in the U.S. for Eylea as a treatment of macular edema following BRVO.

Regeneron (NASDAQ:REGN) maintains exclusive rights to Eylea within the United States. Bayer (NASDAQOTH:BAYRY) holds exclusive marketing rights to the drug in overseas markets except for Japan, where Regeneron (NASDAQ:REGN) receives a percentage of net sales.

Regeneron (NASDAQ:REGN)recently reported that U.S. sales of Eylea, which account for more than two-thirds of its revenue, rose 68% year over year to $1.41 billion in fiscal 2013. Overseas sales of Eylea, mainly contributing to Bayer's (NASDAQOTH:BAYRY) top line, came in at $472 million for a total of $1.88 billion in Eylea sales for the year. Some analysts believe that Eylea still has room to run, with peak sales estimates falling between $3.5 billion to $4.0 billion by 2020.

Cell Therapeutics initiates a phase 3 trial for pacritinib
Meanwhile, Cell Therapeutics (NASDAQ:CTIC) just announced the initiation of a phase 3 trial to test pacritinib, an investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis, a bone marrow disorder that affects blood cell production.

The new trial, known as PERSIST-2, will enroll up to 300 patients in Australia, Europe, New Zealand, and North America within the next 12 to 14 months. PERSIST-2 is the second phase 3 trial testing pacritinib as a myelofibrosis treatment.

Cell (NASDAQ:CTIC) also has two other drugs in phase 3 trials or on the market -- Pixuvri, a treatment for non-Hodgkin's lymphoma (NHL), and Opaxio, an experimental treatment for brain and ovarian cancers. Pixuvri, which is conditionally approved in the EU, is Cell's only marketed product, and generated sales of $1.8 million in the first three quarters of fiscal 2013.

Cell (NASDAQ:CTIC) expects Pixuvri to eventually generate peak sales of $240 million based on the EU approval alone. Sales of pacritinib are expected to achieve peak sales of $750 million, according to Roth Capital Partners analyst Bert Hazlett, if the drug is approved for myelofibrosis along with other blood disorders. If approved, pacritinib will be jointly commercialized with Baxter International.

Investors should note that Cell (NASDAQ:CTIC) is scheduled to report earnings tomorrow after the market close.

AstraZeneca's Bydureon Pen is approved by the FDA
Last but not least, AstraZeneca (NYSE:AZN) announced that the FDA has approved the Bydureon Pen, a prefilled, single-use pen injector filled with the company's GLP-1 drug Bydureon. Bydureon, also known in a different dosage as Byetta, improves glycemic control in adults with type 2 diabetes by "tricking" the pancreas into producing more insulin naturally.

The self-injecting pen eliminates the need for patients to transfer the drug between a vial and syringe prior to self-injection. U.S. Sales of Bydureon are expected to hit $730 million by 2018, according to a report from Bank of America. The approval of the self injector could cause analysts to rethink those estimates, considering that Bydureon/Byetta's biggest competitor, Novo Nordisk's Victoza, can also be injected via a self injecting pen.

AstraZeneca (NYSE:AZN) reported $25.7 billion in revenue in fiscal 2013, so Bydureon still only plays a minor part in the company's overall growth. AstraZeneca (NYSE:AZN) previously shared commercial rights to Bydureon, Byetta, and other diabetes drugs with Bristol-Myers Squibb, but AstraZeneca (NYSE:AZN) bought out Bristol's share for $4.3 billion last December -- indicating that it still sees considerable growth potential in the diabetes market.

One more stock to watch this morning
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

 

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Baxter International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers